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a  b  s  t  r  a  c  t
According  to some  legislation  grouping  can  streamline  data  gap  filling  for  the  hazard  assessment  of
substances.  The  GRACIOUS  Framework  aims  to facilitate  the  application  of  grouping  of  nanomaterials
or  nanoforms  (NFs),  in  a regulatory  context  and  to support  innovation.  This  includes  using grouping  to
enable  read-across  from  (a)  source(s),  for  which  data  and  information  exist,  to  a  similar  target  NF  where
information  is lacking.
The  Framework  provides  an  initial  set  of  hypotheses  for the  grouping  of NFs  which  take  into  account
the  identity  and  use(s)  of  the NFs,  as  well  as the  purpose  of grouping.  Initial  collection  of basic  information
allows  selection  of an  appropriate  pre-defined  grouping  hypothesis  and  a  tailored  Integrated  Approach  to
Testing  and  Assessment  (IATA),  designed  to generate  new  evidence  to support  acceptance  or  rejection  ofisk assessment
egulation
afe(r) by design
ntegrated approach to testing and
ssessment
the hypothesis.  Users  needing  to develop  their  own  user-defined  hypothesis  (and  IATA)  are  also  supported
by  the  Framework.  In  addition,  the  IATA guides  acquisition  of  the  information  needed  to support  read-
across.
This  approach  gathers  information  to  render  risk  assessment  more  efficient,  affordable,  as  well  as
reducing  the  use  of test  animals.
Crown  Copyright  © 2020  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the CC
BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Abbreviations: ECHA, European Chemicals Agency; HARN, high aspect ratio
anomaterials; IATA, integrated approach to testing and assessment; ISO, Interna-
ional Organization for Standardization; JRC, Joint Research Centre; NF, nanoform;
EP, nano-enabled product; OECD, Organisation for Economic Co-operation and
evelopment; PC, physicochemical; Prc, precautionary measures to reduce risk;
EACH, Registration, Evaluation, Authorisation and Restriction of Chemicals; Reg,
egulatory compliance; SbD, safe(r) by design; SNEP, solid matrix nano-enabled
roducts; TSCA, Toxic Substances Control Act.
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d/4.0/).Introduction and aims
Manufacture and functionalisation of materials at the nanoscale
leads to a range of nanomaterials or nanoforms (NFs) (see Box
1) that vary not only in chemical composition, but also in other
physicochemical properties (e.g. size, morphology and surface
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Box 1: Nanomaterials and nanoforms (NFs)
A ’nanomaterial’ is defined only by the size of its constituent
particles according to the European Commission’s (EC) Recom-
mendation 2011/696/EU [1].
The European REACH Regulation [2] has introduced the con-
cept of ‘nanoform’ [3]. Annex VI to REACH states that “a
nanoform is a form of a natural or manufactured substance
containing particles, in an unbound state or as an aggregate or
as an agglomerate and where, for 50 % or more of the particles
in the number size distribution, one or more external dimen-
sions is in the size range 1 nm – 100 nm,  including also by
derogation fullerenes, graphene flakes and single wall carbon
nanotubes with one or more external dimensions below 1 nm”.
A substance may  have one or more NFs, based e.g. on differ-
ences in their number based particle size distribution, shape,
aspect ratio, crystallinity, assembly structure, specific surface
area and surface functionalisation or treatment (REACH Annex
VI, points 2.4.2. – 2.4.5).
Where technically and scientifically justified, grouping and
read-across can be applied within a registration dossier to
two or more NFs for the purposes of one or more information
requirements. However, for grouping different NFs of the same
substance, consideration of the molecular structural similari-
ties alone are not sufficient to serve as a justification (REACH
Annex XI) [3].




































vance in the EU.
haracteristics). Apart from the expected benefits, a modified NF
e.g. coated) may  also affect the environment and human health to
 greater or lesser extent than the unmodified NF (e.g. uncoated).
isk assessment requires detailed physicochemical characteriza-
ion, exposure and hazard data for each unique NF, but testing
very NF would demand substantial resources. More efficient and
ffective ways of characterising physicochemical properties, fate,
ehaviour and (eco)toxicity of NFs are therefore needed, and this
an be achieved by applying grouping and read-across approaches.
For chemicals in general, grouping and read-across are well-
stablished regulatory concepts to minimise the need for specific
esting (e.g. REACH [4], TSCA [5]), and for which guidance is
vailable [6,7]. These approaches are built on well-established
ypotheses that describe how specific hazards can be predicted
ased on a (limited) set of known physicochemical properties and
oxicity testing. This includes gathering the information needed for
 certain hazard endpoint by using data from the most hazardous
ubstance(s) in the group, to cover the rest of the group. A clear rela-
ionship between chemical properties and hazard endpoints needs
o be established in order to allow prediction of missing data for
ome members of the group by interpolation to other members.
In order to streamline the process of implementing grouping
nd read-across for NFs (e.g. within one REACH substance identity),
nd to provide more support for stakeholders such as industry, pol-
cy makers, regulators and academics, the European Union Horizon
020 project GRACIOUS (’Grouping, read-across and classifica-
ion framework for regulatory risk assessment of manufactured
anomaterials and safe(r) design (SbD) of nano-enabled products
NEPs)’; https://www.h2020gracious.eu/) has developed a dedi-
ated framework addressing different purposes for performing risk
ssessment, such as filling in regulatory data gaps, or incorporat-
ng safety into the design of new NFs or NEPs, and is relevant to a
ariety of end users.
The following manuscript illustrates how the GRACIOUS project
as taken existing information, methods and regulatory provisions
described in the Methods section), and used them to identify what
s required to support grouping and read-across for NFs. The GRA-
IOUS Framework aims to:. / Nano Today 35 (2020) 100941
• Support practical and evidence-based grouping of NFs for facil-
itating data gathering for hazard and risk assessment, risk
management and related decision making, thereby meeting the
needs of various global stakeholders, particularly regulators and
industry.
• Develop a number of robust scientific arguments (so called pre-
defined hypotheses) that justify grouping and read-across of NFs
and facilitate the development of new (so called user-defined)
hypotheses.
• Consider not only intrinsic physicochemical properties and
(eco)toxicological effects, but also extrinsic (system-dependent)
descriptors of exposure, toxicokinetics and environmental fate.
• Provide guidance on how the outputs can subsequently be used,
and aligned to the initial purpose of grouping.
• Support decision making spanning regulatory risk assessment
and safe innovation/SbD of NEPs.
• Reduce, refine and replace (3Rs) animal testing for human health
and environmental hazard assessment where possible, by sup-
porting the use of grouping, read-across, modelling and in vitro
tests.
In summary, the GRACIOUS Framework aims to provide prac-
tical guidance on how to conduct both grouping and read-across
of NFs, considering the different exposure scenarios resulting from
the various applications and life cycle stages of NFs in a wide array
of NEPs.
Methods
The following sections summarise the main research, informa-
tion and regulatory considerations which influenced design of the
GRACIOUS Framework.
Grouping approaches that informed the framework design
In recent years, several scientific approaches for grouping and
read-across of NFs have been developed [8,9]; these approaches
have increased in complexity with time, to include an expand-
ing array of parameters. Initially, such approaches were similar to
non-NF approaches in that they focused largely on physicochem-
ical characteristics, and their association with hazards [10–12].
Subsequent projects went beyond hazard and physicochemical
properties of the pristine material, taking into account changes
occurring during the life cycle of NFs [13,14]. This includes NF
transformations in the environment or human body (e.g. changes
in hydrophobicity, agglomeration, zeta potential). Such changes
can subsequently impact upon fate, behaviour, uptake and hazard.
Building on these early experiences, it was  suggested that group-
ing should be supported by information on kinetics (e.g. uptake,
distribution, biopersistence) and early and apical biological effects
[15].
Development of a hypothesis to describe the behaviour of a NF
[16] has also been proposed. In this context, the behaviour is usually
related to a hazard endpoint (e.g. genotoxicity), and is informed by
existing scientific information in a tiered approach, where data are
collected at different levels of complexity. Thus data-gap filling in a
regulatory setting is supported endpoint-by-endpoint, according to
similarities identified from the collected information (mainly based
on chemical identity, physicochemical properties and behaviour in
environmental or biological media) [16].
The first real application of a grouping framework for nano-
materials [17] focused on inhalation as the route of exposure.
This study defined a tiered approach to group nanomaterials
(DF4NanoGrouping project), in which Tier 1 included collection of
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f soluble nanomaterials. This latter information allowed the user
o group soluble nanomaterials along with their molecular coun-
erparts and apply read-across, as well as indicating the testing
equirements of Tier 2. Tier 2 distinguished three other group-
ng options (passive, biopersistent fibres and active materials) by
omparing system-dependent properties (e.g. agglomeration, reac-
ivity, dissolution) against defined cut-off values derived from
enchmark materials. It was proposed that each of the groups may
nform read-across and waiving of testing, as well as providing the
ption for division into sub-groups. Toxicological information (e.g.
rom short term in vivo inhalation studies) was  used in Tier 3 to
orroborate the assignment of the nanomaterial to a group or sub-
roup. Applicability of the framework was subsequently addressed
sing 24 materials of different composition (carbonaceous, metal
xides and sulphates, amorphous silica, organic pigments). The
aterials were assigned to one of the four pre-defined groups
y applying the framework and using available information; the
uitability of the grouping was then assessed on the basis of No
bserved Adverse Effect Concentrations from long-term studies
18].
Building on the DF4NanoGrouping, the nanoGRAVUR frame-
ork added more data requirements to enable grouping by
cological risk and by consumer risk, including aspects of lifecycle
eleases from composite nano-enabled products. Case studies have
xplored which system-dependent properties are most sensitive
14,18].
The complexity of current grouping approaches reflects our
ncreased understanding of the sequence of events in the life cycle
f NFs and the biological pathways, which can influence their
otential hazard [17].
egulatory considerations on grouping
It is important that any grouping framework meant to be used
n a regulatory context aligns to legal requirements. In 2014 the
rganisation for Economic Co-operation and Development (OECD)
oncluded that the application of grouping to nanomaterials was
t that time premature and r̈esearch first needs to pave the way for
t[̈6]. Subsequent expert meetings have aimed to share information
nd discuss categorisation, grouping and read-across of nanomate-
ials [19]. In the EU regulatory framework, possibilities for applying
rouping and read-across approaches for the assessment of nano-
aterials exist but differ in each piece of legislation [20].
In the amended REACH Annexes [3], it is specified that NFs (Box
) should in principle be addressed separately, and that molecu-
ar structural similarities alone cannot serve as a justification for
rouping. In anticipation of these changes, ECHA developed nano-
pecific guidance for grouping, which considers properties beyond
hemical composition to support the hypothesis (e.g. aspect ratio,
article size, shape, or solubility), and highlights the importance
f toxicokinetic studies in grouping, read-across, and for in vitro to
n vivo extrapolation [21,22].
It is worth noting that a group of NFs identified using the GRA-
IOUS Framework is not the same as a ‘set of similar NFs’ as
efined in REACH Annex VI [3,4]. REACH Annex VI specifies that
A ‘set of similar nanoforms’ is a group of nanoforms characterised in
ccordance with section 2.4 [of this annex] where the clearly defined
oundaries in the parameters . . . of the individual nanoforms within
he set still allow to conclude that the hazard assessment, exposure
ssessment and risk assessment of these nanoforms can be performed
ointly”.ead-across approaches that informed the Framework design
Read-across requires development of a robust scientific expla-
ation of similarity to support the use of data on one or more source / Nano Today 35 (2020) 100941 3
materials to fill in a data gap of the target material [4]. A method-
ology for systematically quantifying similarity between NFs for
human hazard assessment, based on physicochemical properties
of NFs (chemical composition, crystalline form, impurities, primary
particle size distribution, aggregate/ agglomerate size distribution,
density and shape) has been reported [23]. This methodology is a
first attempt to use current knowledge on NF property-hazard rela-
tionships to develop a series of pragmatic and systematic rules for
establishing similarity scores. Similarity scores are used to select
the studies that are considered adequate for read-across purposes
and to fill in a data gap in a given hazard endpoint for the NF studied.
Assessment of study quality and relevance are equally important
when selecting that particular study for assessment of NF similarity.
Constructing the overall GRACIOUS framework
Based on the information above, the GRACIOUS Framework was
designed to integrate the industrial (DF4NanoGrouping) [17] and
regulatory [22] grouping concepts. A hypothesis-driven approach
to grouping is essential in order to align with European legislation
(e.g. REACH), but also to provide a scientific basis for any group-
ing decision [16]. The first phase of development of the GRACIOUS
Framework was therefore to identify how grouping hypotheses
could be formulated in a more standardised manner. The Frame-
work description included definitions of key terms and generation
of a diagram explaining how the Framework would be used.
In order to ensure that the Framework would be fit for pur-
pose, the opinions of different stakeholders were sought through
multiple approaches such as:
 One-to-one interviews with representatives from regula-
tion/policy making, standardisation, industry and academia (e.g.
ECHA, European Food Safety Authority, Health Canada, Inter-
national Organization for Standardization (ISO), the National
Institute for Occupational Safety and Health, US  Food and Drug
Administration, Harvard School of Public Health, Department of
Environmental Health, Arizona State University, Nanotechnolo-
gies Industries Association)
 An open online consultation (July – September 2018) receiving
over 30 responses representing Europe, Asia and North America,
as well as academia, policy makers, regulators and industry.
 Inviting feedback through a stakeholder engagement platform
(https://www.h2020gracious.eu/about/stakeholders).
 A stakeholder event co-organised by GRACIOUS and NanoReg2
consortia, held at the OECD in 2018. The workshop brought
together an international audience of 120 participants featuring
representatives from industry, policy-making, regulation, stan-
dardisation and academia.
This feedback has been analysed and edits incorporated in order
to generate the GRACIOUS Grouping and Read-Across Framework
described below. The Framework has been constructed to address
regulatory applications of grouping and read-across. However, the
purposes for which the Framework can be used will be flexible.
Construction of hypotheses for grouping
It was  immediately clear that there was no standardised way
to generate a hypothesis for grouping. A template was therefore
designed to guide the user to structure the available information
in a consistent manner, allowing its integration in order to gener-
ate a hypothesis suitable for grouping [24]. The template includes
sections, which detail:
• The purpose and the context for using the grouping hypothesis,
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The ‘life cycle’ of the NF or NEP (in particular, potential exposure
scenario(s), level of exposure (dose), the released form of the NF),
Descriptions of ‘What they are’ (physicochemical characteristics),
‘Where they go’ (environmental fate and behaviour, uptake and
toxicokinetics) and ‘What they do’ ((eco)toxicological effects),
The ‘potential implications’ of accepting the hypothesis.
During development of the Framework, an in-depth systematic
urvey of the literature, summarised in extensive tables, along with
xpert judgement has allowed identification of over 35 pre-defined
rouping hypotheses that are considered to be evidence-based and
elatively robust (a few examples are provided in Table 1).
The pre-defined hypotheses will be further analysed and pub-
ished in subsequent papers, along with extensive literature
eviews that summarise their suitability for grouping. These pub-
ications will include definition of key terms and suggestions
f either thresholds or similarity assessment criteria for inclu-
ion/exclusion within a group. If grouping by thresholds, then
heses are oriented on biological relevance. The thresholds assign
Fs to predefined groups and thus ensure homogeneity by the
what they are”, “where they go”, “what they do” aspects. E.g. if
he aspect ratio, inflammation potential and dissolution rate in
pecific media are below predefined thresholds for all NFs of the
ame substance, they can be grouped regarding their low acute
nhalation hazard, but potential bioaccumulation can be selected.
lternatively, similarity is assessed on exactly the same descrip-
ors from the decision nodes of the IATAs: We  then compare the
spect ratio, inflammation potential and dissolution halftime of
ll NFs, and exclude outliers, until the remaining group members
ulfil homogeneity criteria. Note that the final IATA will require
ore than the three descriptors used here to represent the “what
hey are”, “where they go”, “what they do” aspects. The scientific
asis of each pre-defined hypothesis will therefore be accessible
nd transparent.
onstruction of the framework IATAs
The IATAs are designed in line with OECD recommendations
25], providing a structured strategy for collecting the required
vidence through the identification and description of the most
ppropriate data sources, models and test methods currently avail-
ble for each endpoint. The strategy, and therefore any testing to
e done, can be tiered to reflect the level of information required
or different purposes and to promote implementation of the 3Rs
rinciples. The tiers of the IATA span from basic information to
he use of in silico tools, in vitro models, extrinsic physicochemical
escriptors, and finally more sophisticated models such as meso-
osm studies (indoor or outdoor experimental systems that study
he wider environment under controlled conditions), 3D in vitro
odels (e.g. organoids, 3D models including multiple cell types,
ab on a chip technologies), and animal models. Not all tiers of test-
ng need to be completed to make a grouping decision. The details
f the IATAs depend upon the route of exposure or environmental
ompartment and will be discussed in detail in several future publi-
ations. Combination of existing information with the IATA outputs
ill allow population of a data matrix that compiles the evidence
ase on which to base a grouping or read-across decision.
dentification of methods to include within the IATAs
Where possible, the methodologies recommended within the
ATAs are well established, based upon peer reviewed literature
nd if possible standardised (e.g. OECD Test Guidelines). For exam-
le, the basic physicochemical information requirements for NFs
re specified in the revised REACH Annexes [3], whereas proper-
ies that should be considered to assess similarity between NFs. / Nano Today 35 (2020) 100941
are recommended in regulatory guidance [22], reviews [26,27],
frameworks [28], grouping approaches [29] and earlier projects
(e.g. NANoREG and nanoGRAVUR [14]). Information on tools, meth-
ods and protocols to be used in the GRACIOUS IATAs to determine
these physicochemical properties is provided in Appendix A.
For assessment of the most relevant form of release, the IATAs
will include methods such as those exemplified in ISO/TC 229 (Nan-
otechnologies) ISO/TR 22293 (in preparation). The similarity of
the released forms is estimated by relevant methods in a step-
wise decision-making process [30] which takes into account the
intended use and its characteristic stresses, the matrix of the NEP,
and the specific NF.
Reference materials and benchmark materials should be used
as controls, to assess whether specific tests have been performed
adequately. Benchmark materials are also essential to calibrate the
amplitude of the response for the target NF for a specific endpoint.
For example, benchmark materials, when used as negative and pos-
itive controls, can provide an understanding of the dynamic range
(maximum and minimum) of response sizes expected for a given
endpoint (Appendix A). This information can then allow analysis
of the relative similarity or dissimilarity between two  or more
forms of a substance (including the target NF). Any comparison
between different NFs or between source and target will require
data obtained by the same method. This is equally required by
US-EPA when comparing different “discrete forms” in their termi-
nology in the reporting of nanomaterials [31].
Analogous to properties that are well-established for molecular
chemicals (e.g. the log Kow), many of the extrinsic properties for
NFs (e.g. attachment affinity or dissolution rate) are assessed on a
logarithmic scale [32]. This scale may  span several orders of mag-
nitude, and a range of values that fall within an order of magnitude,
may  sometimes be considered similar. Such a criterion will need to
be assessed for each property and each grouping purpose.
Potential source materials will be identified through interroga-
tion of the data matrix. The source material may  or may  not be
a reference or benchmark material. Where the benchmark mate-
rials and potential source materials are NFs, as far as possible, the
GRACIOUS Framework will select them from the OECD Testing Pro-
gramme  of Manufactured Nanomaterials [33], available from the
Joint Research Centre (JRC) Nanomaterials Repository [34, as these
are generally well-characterised materials for which a large dataset
is available.
Linking the GRACIOUS framework to a database
To allow the Framework and IATAs to function, they must link
via the GRACIOUS data matrix to existing databases. An initial list
of relevant sources has been derived [35,36], updated and sup-
plemented with more recent information and expert knowledge
from project developments in Europe (7th Framework Programme,
Horizon 2020) and elsewhere, including the “EU US Roadmap
Nanoinformatics 2030” [37]. This allowed the compilation of a con-
temporary picture of the database landscape, covering databases
containing study data, Nano-EHS Knowledge Bases and portals. For
each database, the availability status of experimental data has been
noted (May 2019) in terms of:
• Existing accessible datasets including data within the eNanoMap-
per database (subject to appropriate permissions or Data Sharing
Agreement);
• Data not yet available;
• Potential data source (subject to permissions, Data Sharing Agree-ment and/or upload/indexing to the eNanoMapper database).
Based on this list, the GRACIOUS Framework will be able to
extract existing information and data about source NFs or non-
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Table  1
Brief examples of pre-defined hypotheses. These hypotheses are strongly supported by published literature. Whether a NF can be included within a group is guided by an
IATA  associated with the hypothesis. Inclusion in a group will trigger relatively clear implications. Potential implications are related to 1) supporting activities leading to
regulatory compliance (Reg), 2) steering safe innovation/safe(r)-by-design (SbD), and 3) identifying precautionary measures to reduce risk (Prc).
Pre-defined Hypothesis (scientific rationale) Information needed to determine if the
hypothesis is applicable
Implication type Implications of a NF being placed
in this group
Key Refs
Instantaneous dissolution results in uptake of
the ionic or molecular form. No
nano-specific risks expected.
Substantiate that NFs have a high
dissolution rate in relevant media. This
results in only the ionic or molecular
form reaching the viable cells or
environmental organisms.
SbD, Prc, Reg Assume any effects are only
resulting from the dissolution
products. Read-across from ionic
or molecular form.
[32,50,51]
Non  flexible NFs > 5 nm:  Following dermal
application will not penetrate (in their
particle form) to viable layers of the skin
above 1% of the applied dose.
Substantiate that NFs have low
dissolution in simulated sweat, low
flexibility and sizes larger than 5 nm.
SbD, Reg, Prc If NF is in this group then dermal
penetration is expected to be
minimal (<1%) for healthy skin. If it
is not in this group, design larger
alternatives that are unlikely to
penetrate skin.
[52,53,54,55,56]
Respirable, biopersistent, rigid HARN over a
threshold length of 5m: Following inhalation
and translocation of NFs to the pleura, where
mesothelioma development can occur.
Substantiate low dissolution rate,
rigidity and the dimensions of all NFs
in  the provisional group are in the
critical range known from benchmark
materials.
SbD, Prc Assess alternatives that do not
fulfil this group’s criteria, and thus
prevent the potential of the NF to
cause lung fibrosis, lung cancer and
mesothelioma.
[57,58,59,60,61]
Reg  Targeted testing to assess if
concerns associated with
mesothelioma apply.
Reg, Prc Read-across from asbestos or from
another rigid HARN may  be
possible.
Very  slowly dissolving NFs that form an
unstable dispersion in environmentally
relevant aquatic media can be grouped:
Following aqueous exposure NFs in this group
will settle to benthic systems and can cause
lethal/sub-lethal toxicity to representative
Substantiate a very slow
dissolution/transformation rate and
instability of dispersion.
SbD, Prc Assume NF is biopersistent and
may  lead to long long-term toxicity
in sediment.
[32,62,63,64]
Substantiate similar very slow
dissolution/ transformation rate and
similar instability of dispersion.
Reg Read-across from aquatic pelagic
species is not possible. Read-across






























B Thresholds and similarity criteria for e.g. dissolution rate, and reactivity, to be p
Fs wherever available. Each accessible dataset will have to be
ssessed for completeness of the (meta)data [38]. The GRACIOUS
roject will, where possible, fill data gaps identified in existing
ccessible datasets for key benchmark materials as well as for a
umber of GRACIOUS case study materials that will be used to test
he Framework.
dentification of terminology relevant to grouping and read-across
In order to allow clarity and compatibility with other nanosafety
nitiatives, harmonised terminology is used in the Framework.
armonised terminology relevant for nanosafety was developed
n NANoREG [39] in line with existing terminology in OECD and
U legislation. Similarly, six terms have been identified as key
o the GRACIOUS Framework (Appendix B), namely nanomate-
ial, nanoform, grouping, read-across, SbD, and representative test
aterial/reference material. For most of the terms, the NANoREG
armonised definition, where one exists, has been used as a basis
nd updated in view of new developments.
ead-Across
For read-across, there is a need to provide scientific justifica-
ion that the target material is similar to or less hazardous than the
ource for that specific endpoint. Information on one or multiple
ndpoints from one or more existing NFs can be used to predict
he same endpoint(s) for a similar NF, if proposed for the same use.
his can inform the need for additional studies, risk management
easures, or communication on potential safety issues along the
EP value chain. Read-across is typically used in a regulatory set-
ing, though it is also relevant for SbD. The required level of detail
f information on safety increases as the Stages of product devel-
pment progress (see SbD). Furthermore, when read-across can beand toxicity in benthic species
ed by GRACIOUS.
applied for one or multiple endpoints, this may  lead to more cost-
efficient gathering of information for regulatory registration before
market launch. It may  be possible therefore to anticipate the regu-
latory application of read-across early in the development progress,
so that less resources may  be needed for information gathering for
subsequent regulatory approval.
As indicated before, read-across requires that the target mate-
rial is similar enough to or less hazardous than the to be grouped
together and share data for one or more endpoints [4]. A com-
parison of their similarity related to one or more endpoints is
performed. Similarity may  be considered based on two  principles.
The read-across hypothesis can be based on either structurally
similar NFs having similar properties, or on the principle that
(bio)transformations lead to common exposure-relevant forms of
the material [4].
A read-across case should consider information on:
• Physicochemical properties (“what they are”),
• Fate/toxicokinetic behaviour (“where they go”) related to the
endpoint (e.g. will the target site be reached in a similar way,
and to a similar or lesser extent?),
• A comparison of hazard (“what they do”) also related to the end-
point (e.g. will the same toxicological mechanism be triggered,
and to a similar or lesser extent?).
Assessing the quality of information
Regarding the general criterion’ Reliable and adequate source
data’, ECHA recommends that each study result used in a read-
across case (either to justify read-across or to predict the missing
data for the target member) is evaluated in terms of relevance,
reliability and adequacy [40]. For chemicals, reliability is defined
by the OECD and under REACH it is generally addressed by apply-
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ng the Klimisch criteria [41] as implemented in the ToxRTool [42].
owever, for many of the nano-specific properties, including those
equired by the revised REACH Annexes for NF characterisation
nd recommended by ECHA for grouping of NFs, there are cur-
ently no internationally accepted testing guidelines available, or
he applicability of existing test guidelines is questioned. As a result
limisch scores are currently worse by at least one digit as com-
ared to chemicals in general. It is worth noting that progress is
eing made in the OECD, but for most of the guidelines, adoption
ill still take some years. Furthermore, in the case of data obtained
rom (eco)toxicological studies with NFs, it is critical that physic-
chemical characterisation of the material(s) in the test system is
vailable (in addition to characterisation of the pristine material(s))
43], which is not directly reflected in Klimisch scores. Klimisch
cores also contain some subjectivity for scores higher than one.
or these reasons they may  not be the best option for evaluating
tudy results on NFs [44].
Several alternative evaluation methods of data quality for nano-
aterials have therefore been considered for use within the
ramework. These methods make the process of assessing data
uality less subjective by giving clear criteria for the quality for
anomaterial studies:
 For human health risk assessment:
- Two-step process [43];
-  DaNa Literature Criteria Checklist [44]; and
- GUIDEnano quality assessment approach [45].
 For environmental risk assessment:
- NanoCRED evaluation method [46] and
- GUIDEnano quality assessment approach [45].
afe(r) by design (SbD)
Portfolio management tools such as Stage-Gate aim at stopping
he innovation process if there is unacceptable compromise in (i)
rofitability, (ii) technical probability of success, (iii) commercial
robability of success, and/or (iv) risks or uncertainties regarding
isks [46].
The NANoREG and NanoReg 2 SbD concept proposed a screen-
ng strategy to identify and characterise risks associated with NFs,
EPs or manufacturing processes at early stages of innovation. This
equires determination of ’potential for risk’ at Stage 1 (i.e. lists of
otential scenarios, risks and uncertainties), ’indicators for risk’ at
tage 2 (theoretical risk analysis based on existing data and sub-
ective information) and Stage 3 (experimental risk analysis), and
demonstrators of risk’ at Stage 4 and 5 (risk assessment as laid
own in regulatory requirements) [39,47]. The uncertainty there-
ore reduces progressively along the innovation process according
o the Stage-Gate innovation model, being large and subjective
hen a decision is made at Gate 1, and becoming substantially
maller (driven by legislation) at Gate 5 [39].
esults - the GRACIOUS framework for grouping and
ead-across of nanoforms
ramework overview
This section provides a brief overview of the GRACIOUS Frame-
ork. A more detailed description is provided in the sections below.
The GRACIOUS Framework is structured according to evidence
upported decision nodes (Fig. 1 – boxes with an orange border),
hich guide the user through generating the information needed
o develop a justified grouping and/or read-across decision. Either
 single NF or a provisional group of NFs can represent the entry point
o the Framework.. / Nano Today 35 (2020) 100941
The first step is to gather basic information about the NF or
provisional group of NFs. This includes a selection of physicochem-
ical properties (predicted or known), consideration of the purpose
of grouping and identification of the intended use(s) of the NF(s)
under investigation. The latter allows derivation of the relevant fate
pathway and exposure route(s).
The basic information is used to identify a scientific hypothesis
to facilitate grouping. At this point the user can assess the applicabil-
ity of pre-defined hypotheses for grouping for the investigated NF(s).
If a pre-defined hypothesis is applicable,  the GRACIOUS Framework
will provide a tailored IATA to substantiate the similarity concept
underlying grouping. The term IATA describes the combination of
different types of modelling, testing and assessment approaches,
plus it is frequently used in a regulatory context (e.g. OECD). The
term IATA is used as defined in OECD Guidance Document 255 [48].
Each tailored IATA is specific for a given pre-defined hypothesis and
recommends a series of tests to the user to verify the applicability
of the hypothesis for the material under investigation. As the valid-
ity of these tests, the proposed thresholds or similarity criteria and
the implications of being in the group associated to the hypothesis
have already been investigated, such an approach allows for easy
application of grouping. In addition, options for developing read-
across justifications are provided. For hazard testing the IATAs span
acellular, in vitro and in vivo test systems of varying complexity.
If the predicted or measured information via the IATA sug-
gests that a pre-defined hypothesis is not applicable,  then a new
user-defined hypothesis can be generated via use of our hypothesis
template [24].
To further strengthen a grouping or read-across decision, more
information may  be required to demonstrate similarity between
the source and target NFs or non-NFs and justify the applicability
of the hypothesis (i.e. Does the NF fit in the group?). Generation of
this information is guided via the tailored IATA and gathered in a
data matrix.  This allows methodical and efficient assessment of the
evidence against justification criteria.
The following sections describe the Framework in more detail.
Getting started
• Entry point - Which NF(s) are the focus of the assessment?
The user can enter the Framework with either a single NF or a
provisional group of NFs. These may  be existing materials that are
already on the market, or they may  be in the design phase. In the
case of a provisional group of NFs, the goal is to establish whether
two or more NFs can be grouped together based on a hypothesis
by assessing their similarity with respect to criteria that are of rel-
evance for the hypothesis. Similarly, for a single NF, the goal is to
see if this NF can be assigned to a pre-defined group, also based
on similarity. In both cases the hypothesis needs to be verified and
justified.
If the NF does not fit to a pre-defined group, the Frame-
work can be used to establish a provisional hypothesis-
based group, via searching the eNanoMapper database at
search.data.enanomapper.net (see section 2.8), to identify suitable
source NF(s) or non-NF(s). The GRACIOUS experimental data will
be made public via the eNanoMapper database at a later date. Rel-
evant properties will be used as search terms as indicated in the
approach by GUIDEnano [23]. If these are not known, they can be
identified by use of the IATA.• Basic information
The next step is to collect and assess the available basic infor-
mation via use of a structured matrix. This information is used to
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Fig. 1. Overview of the GRACIOUS Framework for Grouping and Read-Across of nanoforms (NFs). The Framework diagram demonstrates the key decision nodes (boxes
























afe(r)-by-design (SbD) than for data gaps filling in regulatory context). Abbreviatio
not  sig), very slow dissolution (v slow diss), dissolution (diss), toxicity (tox), mol
anoform (NF).
dentify whether a pre-defined hypotheses is appropriate, and/or
o generate a user-defined, tailor-made grouping hypothesis.
o Identify the purpose of grouping
The GRACIOUS Framework is useful:
 To support regulatory compliance (including read-across)
When compiling dossiers for regulatory purposes (e.g. REACH
egistration dossiers), grouping can be used to fill data gaps for
 substance using data available on similar substances instead of
onducting particular tests. This includes the possibility to apply
ead-across, see section 2.10. Note that the source substance could
e another NF, a larger particle or molecular form (a non-particulate
ersion of the same chemical) registered in the same dossier.
 To facilitate more efficient hazard testing
A clear scientific hypothesis for grouping similar NFs, focused on
 hazard endpoint (e.g. ability to induce inflammation), helps to tar-
et information gathering, assessment and test design. In addition,
nclusion within the hypothesis of specific exposure routes (e.g.
uman inhalation) or environmental compartments (e.g. aquatic),
urther refines the choices for information gathering and testing.
 To steer safe innovation / SbD processes
Testing for safety during the development phase of a material
as to be cost-efficient. The GRACIOUS Framework therefore aligns
ith the Stage-Gate model [49] in order to ensure relevance of the
ramework to business decision-making.
 To identify precautionary measures to reduce exposure
At any time during NF/NEP development or use, the Framework
an help to identify adequate risk management measures by pro-
iding information on similar materials and uses for which such
easures are already established. An examples of risk manage-
ent measures include reducing exposure (e.g. via enclosure of alude physicochemical (PC), high aspect ratio nanomaterials (HARN), not significant
(mol), Integrated Approach to Testing and Assessment (IATA), information (info),
process to prevent the release of NFs, or coating of a NF to reduce
dustiness).
 To improve scientific understanding
Grouping could help to improve the understanding of mecha-
nistic toxicology of certain NFs. Grouping also allows identification
of a NF’s physicochemical descriptors, exposure contexts, transfor-
mations and mechanisms of hazard that drive risk. Construction of
the IATAs also allows identification and prioritisation of relevant
methods to be developed or standardised.
- Early clarification of the purpose of grouping allows the user to:
- Recognise whether grouping is suitable for the purpose proposed,
- Identify the extent and detail of information required to support
grouping,
Recognise the acceptable level of uncertainty, taking into
account the scientific robustness of the similarity hypothesis and
the quality of the data used to justify it.
At this stage, users will need to consider if grouping will be
the most effective approach in terms of saving time, costs and/or
test animals. Where the substantiation of grouping would require
considerable testing, it may  be more appropriate to gather the
required information for each NF individually. In general, for (a)
large group(s) it may  be more challenging to justify the grouping.
In addition, it is useful to consider the implications of placing a NF
inside a group, outside a group, or in multiple groups (for multiple
endpoints).
o Basic physicochemical (PC) information – What they are
The basic physicochemical information should, as a minimum,
enable characterisation of the pristine NF(s), helping the user
to consider relevant hazards (what they do) and/or fate/kinetics
(where they go). Physicochemical data allows a first assessment
of similarity between NFs, for which information is available and
which may  be used either as benchmark materials for testing and/or
as source materials for read-across. At this stage, the basic physic-
ochemical information may  be predicted or known. An advantage
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f using predicted information is that the most relevant grouping
ypotheses can be easily identified, reducing the need to assess
ess relevant hazard endpoints. Predicting basic information is most
elevant for safe-by-design or targeted testing. The basic informa-
ion reflects regulatory requirements. For regulatory application of
rouping and read-across, this information should thus be known
lready rather than predicted.
Within the GRACIOUS project, the following physicochemical
roperties are required as basic information for the pristine mate-
ial: composition, crystallinity, particle size, specific surface area,
ustiness, water solubility (incl. dissolution rate), density, surface
ydrophobicity, surface charge, shape, chemical nature of the sur-
ace (henceforth s̈urface chemistry)̈.
Of these properties 6 are considered priorities: composition,
rystallinity, particle size, shape, surface chemistry, and specific
urface area [38]. The above list consists of intrinsic properties that
re considered to be essential to uniquely identify a NF, and is in
ine with the NF registration requirements of the revised REACH
nnexes [3].
o Release and exposure scenarios – descriptors for the intended
uses
The Framework includes decision trees which guide the user to
pecify:
 Intended use and physical form during use (e.g. whether the NF
or NEP is used as a powder, suspension or aerosol).
 If the NF is associated with a matrix of the NEP (e.g. surface coat-
ing, matrix-embedded or mixed powder) and the characteristics
of this matrix.
 Potential release pathways and exposure route(s) to humans and
the environment (within relevant compartments).
The NF functionality in the intended use determines many of the
F physicochemical properties (composition, size, reactivity, per-
istence) that then also influence options for grouping with respect
o hazard, fate, exposure. For example, pigments for transparent
oatings in food contact need to have sizes around 30 nm and need
o be insoluble to achieve the desired functionality, but the same
roperties can be the basis to establish groups with respect to haz-
rd. These life cycle considerations (exposure scenario descriptors,
redicted or known) help the user to select the hypothesis more
pecific considering the exposure relevant nanoform, exposure
oute and potential dose range of exposure. All of this information,
n turn, helps to further refine the IATA to generate the most impor-
ant information required to support grouping (and subsequently
ead-across). At this stage, the release and exposure scenarios may
e predicted or known.
sing the basic information to identify a hypothesis for grouping
Assess applicability of a pre-defined hypothesis for grouping
The hypotheses in Table 1 are ‘pre-defined’ in terms of both the
cientific evidence supporting them and the understanding of the
mplications for risk assessment of placing a NF in each group.
For early-stage industrial SbD decision-making, or for precau-
ionary risk management, final decisions may  already be made
t this node. For example, if the High Aspect Ratio Nanomaterial
HARN) grouping hypothesis applies to the NF(s) under investi-
ation, one may  recommend NF(s) substitution or procedures to
anage safe use (e.g. avoid abrasive modification of the solid matrix
anoenabled product) without further testing.
Pre-defined hypotheses of this nature provide an opportunity
o quickly assess whether a NF fits into such a group and directs. / Nano Today 35 (2020) 100941
focus to the information-gathering required to justify the group-
ing decision. The GRACIOUS Framework is designed to provide
evidence-based thresholds indicating the cases in which pre-
defined hypotheses may be applicable, based on comparison to
benchmark materials that are specific to each hypothesis.
As previously indicated, if the pre-defined hypotheses are not
applicable, then a ‘user-defined’, tailor-made hypothesis can be
generated via use of a hypothesis template. When a NF aligns with
more than one pre-defined hypothesis, the user can select the one
that best serves the specific purpose. For example, for a carbon
nanotube intended to be embedded in a nanocomposite, in an occu-
pational scenario where the manufacturing processes might lead to
release of free NFs, the HARN hypothesis may  be more applicable. In
contrast, in the finished goods, where one aims to prevent exposure
of consumers to free NFs, a hypothesis relating to the relatively low
release of NFs from a solid matrix may  be a more relevant consumer
product scenario.
Note that for release, the grouping hypotheses detail the life
cycle processes (considering the intended use) that exert similar
energy on the NF or NEP (mechanical, thermal, etc.), matrices with
similar resilience, NFs with similar dustiness, or grouping by arti-
cle category. For read-across, the hypotheses address whether the
combination of process/matrix and NF leads to similar release rates
and similar released forms for source and target NFs or NEPs.
Regarding exposure, grouping utilises the REACH descriptors for
defining exposure scenarios (process, matrix, NF/NEP and expo-
sure factors: exposure route, exposure controls, duration of the
activity/use, amount of NF being handled). Read-across of hazard
information is most appropriately conducted across similar scenar-
ios.
Assessing whether a hypothesis is justified
• Use of Tailored IATAs to assess applicability of a group or to guide
read-across
As outlined above, each hypothesis triggers development of a
tailored IATA which evaluates all properties that are relevant for the
hypothesis, allowing the grouping to be either accepted, rejected,
or to indicate where further information is required for a specific
purpose. The tailored IATAs include assessment of those descrip-
tors (e.g. physicochemical parameters and hazard biomarkers) that
are critical to decide whether the NF(s) investigated fits within the
group described by the hypothesis, or whether the source and tar-
get NF(s) are sufficiently similar to apply read-across. As the validity
of these tests, proposed thresholds or similarity criteria, and the
implications of being in the group associated to the hypothesis have
been scrutinised scientifically, the hypothesis and the information
gathered according to the IATA thereby provides the grouping jus-
tification. Because the IATAs are tailored to the hypothesis, they
have the added advantage that they guide the user not to generate
non-essential information or data.
Not all tiers of testing outlined in the IATAs need to be completed
for each application of grouping, depending on the level of similar-
ity of the NFs under investigation. With respect to assessing release
and exposure during the life cycle, the IATA developed in GRA-
CIOUS will detail the release form and/or release rates/exposure
concentration, where possible, to be used as input information for
a fate and hazard-based hypothesis. Following the Use Descriptor
System developed by ECHA [49], the descriptors for occupational
process categories, product categories for consumer exposure and
the environmental release categories are used as grouping descrip-
tors. While these may  not be optimal for input information for a
hypothesis, they have the benefit of being relatively easily available.
Information generated by the IATAs will be collected into the
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eject or accept the hypothesis. In order to be effective the data
atrix requires robust links to relevant databases that facilitate
oth acquiring existing data, as well as storage of newly acquired
ata for future use. For confidential data, this can be included in the
ata matrix without public access to these specific data.
The ability to group nanoforms or apply read-across depends
n an assessment of their similarity for specific endpoints (hazard,
ate/toxicokinetics, physicochemical and exposure) that relate to
he decision nodes in an IATA. The Framework guides the user to
igher tiers of testing to decrease uncertainty or to consider the
anoform on a case by case basis
Check Justification criteria for purpose and quality of information
for making a grouping or read-across decision
Assessment of the quality of the information used for grouping
r read-across is also essential. Via the tailored IATAs the GRACIOUS
ramework guides the user in evaluating:
 The adequacy of the hypothesis,
In terms of adequacy, the IATA will guide the user through
roduction of the documentation required to justify a grouping
ypothesis and application of read-across. The general criteria are
ummarised in Appendix C. In future case studies we will provide
xamples and clarification of how these justification criteria can be
pplied.
By providing the scientific basis of each pre-defined hypothesis
nd, where possible, by suggesting evidence-based cut-off values,
he Framework will indicate the scenarios in which these pre-
efined hypotheses may  be applicable. These assessments facilitate
 conclusion on whether the grouping hypothesis is sufficiently
ustified for the purpose.
 The quality of the information used to test the hypothesis,
Park et al. 2018 [23] provide a powerful tool for data quality eval-
ation of both toxicological and ecotoxicological studies performed
ith NFs. This approach can be combined with some aspects that
re covered in other schemes, for example DaNa and NanoCRED,
hich provide added value by further exploring the appropriate-
ess of the method and study setup.
sing the GRACIOUS framework for read-across
For grouping, the hypothesis relates to whether NFs (and non-
Fs) are sufficiently similar with respect to a specific endpoint
e.g. dissolution) to be considered as members of a group. In com-
arison, for read-across, the hypothesis focuses on filling specific
ata gaps by addressing whether the target NF is likely to have a
imilar hazard or is less hazardous than the source NF(s) or non-
F(s). Establishing a group of two or more NFs facilitates filling
ata gaps for data-poor group members by read-across from data-
ich ones, supporting both regulatory and innovation purposes (i.e.
rouping generally precedes read-across). Such read-across can be
erformed, for example, when a very similar or smaller amount of
he target material is observed to reach the target site, in combina-
ion with a similar or lower hazard potential than that of the source
aterial(s) (Fig. 2).
Specific examples of read-across include the case of instanta-
eous dissolving NFs, for which read-across from the solute for
ultiple endpoints is proposed, whereas for high aspect ratio
anomaterials read-across from asbestos is possible. This section
utlines how the same Framework can be used for read-across
eyond the pre-defined hypotheses. / Nano Today 35 (2020) 100941 9
Fig. 2 starts by guiding the user to identify potential source
NFs and non-NFs, and the development of a robust scientific jus-
tification of similarity between the source material(s) and target
NF(s). As described above for grouping, the basic physicochemical
information helps the user to generate a read-across hypothesis for
a specific endpoint. Physicochemical descriptors for an exposure-
relevant pristine or transformed NF may  also be derived through
life cycle considerations during the initial grouping, or through sub-
sequent application of the tailored IATA for ẅhere they go.̈  These
descriptors can be used to identify source materials analogous to
the exposure-relevant NF as part of a read-across assessment for a
specific instance of exposure or release during the NEP life cycle.
In order to substantiate the read-across hypothesis, the Framework
allows the user to identify relevant available information on hazard
(what they do) and/or fate/kinetics (where they go) via applica-
tion of the tailored IATA. This process includes assessment of those
descriptors (e.g. physicochemical parameters and hazard biomark-
ers) that are critical to deciding whether the source NFs or non-NFs
and the target NF are sufficiently similar, or to show that the tar-
get NF has a lower risk compared to the source NF. The Framework
subsequently guides the comparison of the target NF and source
materials, allowing focus on the specific properties that define simi-
larity. As for grouping, the criteria to assess whether the read-across
is sufficiently justified depend on the purpose.
Using the GRACIOUS framework for SbD
Considerations based on similarity may  be used to derive a con-
clusion on risk potential in the SbD process. For example, a designed
NF can be assessed for similarity with its non-nanoform(s), or
another NF for which information is available. This may  also indi-
cate possibilities for developing a read-across justification rather
than performing general testing to comply with regulatory require-
ments at a later stage [47]. This can be achieved by manipulation
of the stringency of the justification criteria. For example, grouping
for regulatory purposes would only include NFs consisting of one
substance per group, whereas for SbD multiple substances could be
included within the same group.
A hypothesis at Stage 1 (Research/Business idea) could be formu-
lated based on expert judgment and existing information, without
the need to build a robust scientific justification and without the
need to provide the full documentation. At this stage more uncer-
tainty is often accepted and the precautionary principle is usually
applied to ensure that the designed NFs or NEPs, with potential
elements of high hazard or exposure, are properly managed by the
design process, allowing product exclusion at early Gates (Gate 1)
of the Stage-Gate process (Fig. 3).
However, high uncertainty at Stage 1 could also allow progres-
sion of a NF or NEP to Stage 2, where more extensive testing will help
to reduce uncertainty and aid decision making. This progression
in complexity of information requirements to reduce uncertainties
corresponds with the increasing complexity of the models or assays
used in the tiers of testing outlined in the IATAs (Fig. 3). The IATAs:
• Provide screening-level hazard assessments based on in silico
modelling before the “Go to development” decision at Gate 3.
Specifically, QSAR models and machine learning approaches (e.g.
nonlinear Principal Component Analysis, matrix factorization,
deep learning autoencoders) can help to cost-effectively iden-
tify key nano-bio/eco interactions and Modes of Action in the
early stages of innovation as a basis to establish hypotheses for
grouping and rules for read-across. These models can also be
applied to predict hazard endpoints based on physicochemical
data. Moreover, PBPK models can be employed to model the tox-
icokinetics/dynamics of the materials in the human body as a
basis for in vitro-in vivo to human extrapolations. This can help
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Fig. 2. Developing a read-across justification for one or more NFs for a specific endpoint (Figure adapted from Oomen et al., 2015). For substantiation, in vivo testing can
become necessary if the evidence by physicochemical, in silico, in vitro methods remains inconclusive at the required level of justification criteria.
F a the S
i e IATAig. 3. Outline for the relationship between the GRACIOUS Framework and SbD vi
nitial  tier of the IATAs, while the orange arrows relate to mid  and higher tiers of th
to use/read-across existing physicochemical and in vitro toxicity
data for SbD purposes, which can substantially reduce costs and
eliminate the need for animal testing before Gate 3. To enable
this, we shall directly use such modelling approaches as part
of the IATA. The available in silico tools that we have identified
as relevant for the GRACIOUS framework have been thoroughly
reviewed by the project and are described in [65].tage-Gate Idea-to-launch innovation process. The blue arrows are relevant to the
s.
• Support SbD decisions at Gate 3, by allowing an acceptable level of
uncertainty. For example, it is sufficient to know that the intended
use and the resilience properties of the NEP matrix are similar to
those of a well-known reference NEP.• Support SbD decisions at Gate 4, by aligning the risk assessment
of the NF with that of a similar source substance. Here similarity
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target NF being within the same (few) order(s) of magnitude. The
thresholds or similarity criteria are typically derived from the
dynamic range of values generated through testing of the positive
and negative controls.
Support SbD decisions at Gate 5, by feeding into the preparation
of a regulatory dossier, with the aim of fulfilling the information
requirements without (additional) animal testing. For hypothe-
ses with clear implications, the data generated at early IATA tiers
would generally suffice to substantiate the grouping or read-
across. For user-defined hypotheses, and for data requirements
at high tonnages, substantiation may  require Tier 3 testing.
More robust criteria for justification of a hypothesis would
herefore be required at Stages 4 and 5, to align the safety assess-
ent of the selected NF or NEP with the regulatory requirements
See Appendix D), even before the registration or approval process
tarts. The criteria to assess the scientific adequacy of grouping and
ead-across justifications are provided in Appendix C. The practical
pplicability of the general criteria in Appendix D in a SbD context
ill be verified on a case-by-case basis through the GRACIOUS case
tudies.
onclusions and future outlook
The GRACIOUS Framework builds upon and combines concepts
rom multiple previous and current projects, as well as guidance
rom regulators (notably REACH, but also product specific regula-
ions and non-European legislation). The Framework supports the
se of grouping hypotheses related to one or several endpoints.
he Framework also supports demonstration of the adequacy of
he hypothesis and development of a grouping or read-across jus-
ification in view of the similarity between NFs. The Framework
dentifies key information and data requirements to substantiate
pecific grouping hypotheses. It also provides the most relevant
rotocols to generate the data and information needed to test the
ypotheses and it structures these tests via a scientifically based
ATA.
As suggested by other projects [16], there is a wealth of infor-
ation available about the safety of NFs that can be employed in
isk-related decision making. The GRACIOUS Framework is there-
ore designed to use hypotheses and associated IATAs to promote
he use of existing information and data, combined with modelling
nd generation of new data.
Both the DF4NanoGrouping and the ECHA concepts recommend
hat the data needed for applying grouping and read-across to
Fs is obtained in a cost-effective manner. The GRACIOUS Frame-
ork tailored IATAs therefore enable the generation of adequate
nformation to substantiate a number of pre-defined grouping
ypotheses, starting relatively simple and increasing in depth
nd/or complexity where uncertainty needs to be minimised. The
ATAs may  also be used to develop and justify other hypotheses for
rouping and read-across.
In order to ensure sustainability, the final Framework will be
pen for easy integration of new knowledge, and will be modu-
ar and sufficiently flexible to accommodate new insights, making
he Framework future proof. The first iteration of the Framework
as been constructed to address regulatory applications of group-
ng and read-across. A subsequent version will then be adapted
or the purposes of SbD through reduction of the stringency of the
ustification criteria.
The Framework is synergistic with the 3Rs strategies. A recent
eview [66] has interpreted the “3Rs as a framework to support a
1 st century approach for nanosafety assessment”, and proposed
 tiered approach, elements of which are congruent with the ele-
ents of the GRACIOUS Framework. For example, the first “plane”
f the 3Rs framework described by this review [50] includes intrin- / Nano Today 35 (2020) 100941 11
sic material properties, life cycle use and release. The GRACIOUS
Framework also starts from intrinsic material properties, and posi-
tions the intended use at the interface before targeted testing,
in order to focus on relevant compartments. The elements of the
3Rs-motivated testing strategy in the second “plane” [66], include
uptake, biodistribution, biopersistence, biophysical interaction and
cellular effects. These are highly consistent with mid-tiers of the
GRACIOUS IATAs; however, the GRACIOUS Framework also seeks
to incorporate assessment of environmental endpoints.
While the GRACIOUS Framework is primarily designed to work
under European legislation, the Framework could also be of global
relevance in risk assessment and management. Among the stake-
holders engaged by GRACIOUS are regulatory bodies from the USA
and Canada, and so more will be done in the future to consider the
applicability of the Framework outside the EU.  Wherever possible,
the Framework will refer to OECD Test Guidelines and Guidance
Documents in order to support mutual acceptance of data. Also
references to standards, e.g. from ISO, will be included, and both
ISO and OECD have global relevance.
While the Framework we present here is extensively developed,
we anticipate that during construction of the individual elements
(e.g. the IATAs), consultation with stakeholders and testing on case-
studies, modifications may  be required in order to generate the final
functional version (to be launched in 2021).
In summary:
• The GRACIOUS Grouping Framework design
o aligns with EU chemicals legislation (in particular REACH) in
order to facilitate use of grouping and read-across in a regula-
tory setting, which will also be globally relevant;
o is informed by existing approaches and recommendations on
grouping and read-across;
o aligns with the industrial innovation process (e.g. Stage-Gate
Idea to Launch process);
o is hypothesis-driven and evidence-based.
• The information and data for justifying the grouping hypotheses
are generated via a tailored, scientifically-based IATA. Potential
implications of grouping according to the hypotheses are indi-
cated.
• The IATA is of increasing specificity and complexity and serves to
acquire the data needed to justify grouping and read-across.
• Grouping considers not only intrinsic properties and toxicologi-
cal effects, but also extrinsic (system-dependent) descriptors of
exposure, toxicokinetics and environmental fate.
• The outcome of grouping is influenced by the grouping purpose
(regulatory compliance including read-across, innovation/SbD,
identification of precautionary measures, scientific understand-
ing) and context (e.g. inhalation vs dermal, or human vs
environment).
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